Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Recently, Hong Chow, Executive Vice President of Merck and Head of China & International for Merck Healthcare, led a delegation on the first "China Visit" of 2025, reaffirming that collaboration ...

bought global rights to China-based United Laboratories International’s weight-loss drug candidate in a deal worth up to $2 billion. Merck last year signed a licensing deal worth up to $2 ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...